Article

HER2 Biomarker Testing in Breast and Gastrointestinal Cancers: The Role of the Pathologist

This publication provides a summary of key stakeholder insights on methodological limitations and analytical factors to consider pertaining to biomarker testing for HER2+ across cancer types, with particular emphasis on the role of the pathologist in the multidisciplinary management of cancer.

Related Videos
Sarah Sammons, MD
Laura Spring, MD
Laura Spring, MD
Aatur D. Singhi, MD, PhD
Rondell P. Graham, MBBS
Rachel E. Factor, MD, MS
Corey J. Langer, MD
John F. Lazar, MD
Rodolfo Bordoni, MD
Related Content
Best Practices in Treating Early-Stage NSCLC
July 11th 2024

Best Practices in Treating Early-Stage NSCLC

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer
April 11th 2024

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer
April 21st 2023

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

Clinical Decision Making in Advanced NSCLC without Actionable Mutations
April 21st 2023

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

BTK Inhibitors in MCL and CLL
March 10th 2023

BTK Inhibitors in MCL and CLL

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?
January 25th 2023

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?